Furthermore, Pingitore and colleagues demonstrated that Liraglutide prevents the development of steatosis and COL1A1 level in an in vitro NAFLD model generated as 3D spheroids composed of HepG2 and LX-2 cell lines (Pingitore et al., 2019[42]). The gene discussed is COL1A1; the disease is metabolic dysfunction-associated steatotic liver disease.